People with tremor-dominant Parkinson’s disease experience a higher burden of nonmotor symptoms than people with essential tremor (ET), according to a recent report. Overall nonmotor symptom severity, urinary symptoms, and loss of smell are among the factors that most clearly diverged between the two conditions. Researchers believe the…
Levels of the protein epidermal growth factor, or EGF, in blood may help predict the risk of cognitive decline in people with Parkinson’s disease, a study reports. The study, “Correlation between plasma epidermal growth factor and follow-up cognitive decline in Parkinson’s disease,” was published in Neurological…
A large proportion of people with Parkinson’s disease struggle with sleep problems, including issues with falling asleep or maintaining uninterrupted sleep, according to a large study out of Maynooth University in Ireland. Certain factors, such as being male or receiving a Parkinson’s diagnosis at a younger age, may…
Gardenin A, a compound found in a common South Asian shrub, lessened both cognitive and motor symptoms of Parkinson’s in a mouse model of the disease, according to a study. The compound reduced the loss of dopaminergic neurons — nerve cells that are gradually lost in Parkinson’s— and decreased…
An Australian company announced that it is working on a direct, nose-to-brain way of delivering dopamine that might more effectively treat Parkinson’s disease. PreveCeutical anticipates that this approach, based on what it calls a sol-gel solution that turns into a gel once in contact with mucosa tissue…
The prevalence of early-onset Parkinson’s disease is six times higher among adults with a genetic condition called 22q11.2 deletion syndrome compared with the general population, an international study reported. Previously known as DiGeorge syndrome, 22q11.2 deletion syndrome is caused by a deletion of a small piece of chromosome 22…
Parkinson’s Revolution, an indoor cycling event to spread awareness about Parkinson’s disease and raise funds for the Parkinson’s Foundation, will take place Feb. 22. The virtual cycling event will feature an indoor cycling ride bracketed by an opening and closing ceremony. There also will be chances for…
The diabetes medication exenatide did not slow motor symptom progression in treated Parkinson’s patients relative to those given a placebo, failing at the main goal of a Phase 3 study. Exenatide — sold in the U.S. under brand names including Byetta and Bydureon BCise, and used to help…
The average caregiver for someone with Parkinson’s disease spends more than 30 hours per week doing unpaid work to provide care, and many report substantial emotional and physical strain. That’s according to a new report from the National Alliance for Caregiving (NAC), with support from…
Cyrano Therapeutics is supporting an investigator-initiated clinical study that will evaluate CYR-064, its leading nasal candidate therapy, to restore smell loss in Parkinson’s disease. The study, led by neurologist David Silvers, MD, in Palm Beach Gardens in Florida, seeks to enroll 15 to 20 adults, ages 18-80, with…
Get regular updates to your inbox.
